Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 7;20(14):5474-5494.
doi: 10.7150/ijbs.102032. eCollection 2024.

Targeting Neurological Disorders with Stilbenes: Bridging the Preclinical-Clinical Gap

Md Zamshed Alam Begh  1 , Jishan Khan  2 , Mehrukh Zehravi  3 , Sherouk Hussein Sweilam  4   5 , A Dinesh Raja  6 , A Muthukumar  7 , M Akiful Haque  8 , Nihar Ranjan Kar  9 , Laliteshwar Pratap Singh  10 , B Dharani Priya  6 , Mohammed Ali Alshehri  11 , Irfan Ahmad  12 , Sojin Kang  13 , Seungjoon Moon  13 , Moon Nyeo Park  13 , Talha Bin Emran  1   14 , Bonglee Kim  13
Affiliations
Review

Targeting Neurological Disorders with Stilbenes: Bridging the Preclinical-Clinical Gap

Md Zamshed Alam Begh et al. Int J Biol Sci. .

Abstract

Neurological disorders (NDs) encompass a range of debilitating conditions that affect the nervous system, including prevalent illnesses such as Alzheimer's disease, Parkinson's disease, and ischemic stroke. Despite significant ongoing studies, effective therapeutic strategies to halt or slow down the progression of these illnesses are still lacking. Stilbenes, a class of natural polyphenols, have shown potential as candidates for therapeutic strategies due to their capacity to protect the nervous system. Preclinical studies have provided strong evidence that stilbenes can regulate many cellular pathways implicated in neurodegeneration, with resveratrol being a well-studied compound that has shown the ability to reduce oxidative damage, promote neurogenesis, and enhance mitochondrial function - crucial for maintaining brain health. In preclinical animal models, initial research has also shown promise in additional substances such as piceatannol and pterostilbene. Furthermore, clinical studies have explored the therapeutic benefits of stilbenes in NDs. Despite promising results in preclinical research, the use of stilbenes in clinical trials is currently limited, with most studies focusing on resveratrol. Although several clinical studies have demonstrated the beneficial impact of resveratrol supplementation on brain health and degenerative consequences, other investigations have yielded ambiguous findings, underscoring the urgent need for more comprehensive and precisely planned clinical research. This study delves into the potential benefits of stilbenes as neuroprotective agents for NDs. It emphasizes the need for more clinical research to enhance our understanding of their therapeutic effectiveness in specific patient groups.

Keywords: Chemistry; Clinical studies; Neurological disorders; Preclinical studies; Stilbenes.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Chemical structure of stilbenes.
Figure 2
Figure 2
Stilbenes as therapeutics for Alzheimer's disease. The figure was designed by the Biorender.com program (https://biorender.com/, accessed on 1 May 2024).
Figure 3
Figure 3
Stilbenes as therapeutics of Parkinson's disease and Huntington's disease. The figure was designed by the Biorender.com program (https://biorender.com/, accessed on 1 May 2024).
Figure 4
Figure 4
Resveratrol as therapeutics of Multiple Sclerosis. The figure was designed by the Biorender.com program (https://biorender.com/, accessed on 5 May 2024).
See this image and copyright information in PMC

References

    1. Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics. Int J Mol Sci. 2022;23(3):1851. - PMC - PubMed
    1. Huang Y, Li Y, Pan H, Han L. Global, regional, and national burden of neurological disorders in 204 countries and territories worldwide. J Glob Health. 2023;13:04160. - PMC - PubMed
    1. Palanisamy CP, Pei JJ, Alugoju P, Anthikapalli NVA, Jayaraman S, Veeraraghavan VP. et al. New strategies of neurodegenerative disease treatment with extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) Theranostics. 2023;13(12):4138–65. - PMC - PubMed
    1. Bulck M Van, Sierra-Magro A, Alarcon-Gil J, Perez-Castillo A, Morales-Garcia JA. Novel approaches for the treatment of alzheimer's and parkinson's disease. Int J Mol Sci. 2019;20(3):719. - PMC - PubMed
    1. Al Mamun A, Shao C, Geng P, Wang S, Xiao J. Polyphenols Targeting NF-κB Pathway in Neurological Disorders: What We Know So Far? Int J Biol Sci. 2024;20(4):1332–55. - PMC - PubMed

MeSH terms